Target intelligence / Profile preview

RanBP-type and C3HC4-type zinc finger-containing protein 1 (RBCK1)

Target
RBCK1
Molecular classification
Enzyme (specifically, E3 ubiquitin-protein ligase), Component of the linear ubiquitin chain assembly complex (LUBAC), Zinc finger protein
01

Overview

RanBP-type and C3HC4-type zinc finger-containing protein 1 (RBCK1, also known as HOIL-1) is an enzyme classified as an E3 ubiquitin-protein ligase, essential for protein ubiquitination processes and a critical component of the linear ubiquitin chain assembly complex (LUBAC)[3][5]. It regulates protein degradation and stability—particularly through the addition of linear (Met1-linked) ubiquitin chains—and contributes to NF-κB pathway activation and innate immune responses[3][4][5]. RBCK1 plays important roles in cell survival, proliferation, migration, and inflammation, and its dysregulation is implicated in cancer progression (e.g., breast and liver cancers), immunodeficiency, autoinflammatory syndromes, and congenital myopathy[1][2][4]. Targeting RBCK1 or its complex may have therapeutic promise, but may also pose challenges due to its broad roles in immunity and cell homeostasis.

Other names
HOIL-1Heme-oxidized IRP2 ubiquitin ligase 1RING finger protein 54Hepatitis B virus X-associated protein 4Ubiquitin-conjugating enzyme 7-interacting protein 3C20orf18RNF54UBCE7IP3XAP3XAP4PBMEIPGBM1RBCK2ZRANB4
02

Mechanism of action

Drugs targeting RBCK1 would likely act by modulating ubiquitination activity, disrupting LUBAC complex function, or affecting NF-κB signaling[1][2][3].

03

Biological functions

Ubiquitination (protein ubiquitin modification)Regulation of protein stabilityPositive regulation of canonical NF-κB signal transductionRegulation of transcription factor activityImmune response modulationApoptosis regulationCell proliferation and migration
04

Disease associations

Cancer (notably breast cancer, liver cancer/hepatocellular carcinoma)Inflammation (autoinflammatory syndromes)ImmunodeficiencyPolyglucosan body myopathyInfection (e.g., pyogenic bacterial infection, hepatitis B virus-related interactions)
05

Safety considerations

Modulating RBCK1 may impact immune function, inflammation, and muscle function (based on disease associations with immunodeficiency, autoinflammation, and myopathy)[4].
06

Biomarkers

RBCK1 expression level (as a prognostic or diagnostic marker in certain cancers, e.g., breast and liver cancer)[2][4].

Beyond the preview

Go deeper on RanBP-type and C3HC4-type zinc finger-containing protein 1 (RBCK1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RanBP-type and C3HC4-type zinc finger-containing protein 1 (RBCK1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call